MF management by Prithviraj Bose, Srdan Verstovsek

Get full text

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives by Prithviraj Bose, Srdan Verstovsek

Get full text

Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy by Sophia S. Lee, Srdan Verstovsek, Naveen Pemmaraju

Get full text

How we diagnose and treat WHO-defined systemic mastocytosis in adults by Ayalew Tefferi, Srdan Verstovsek, Animesh Pardanani

Get full text

PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA by Melisa Palacio, Srdan Verstovsek, Tomonori Uno, Taishi Yamashita

Get full text

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety by Srdan Verstovsek, Ruben A. Mesa, Robert A. Livingston, Wilson Hu, John Mascarenhas

Get full text

Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis by Ivo Veletic, Sanja Prijic, Taghi Manshouri, Graciela M. Nogueras-Gonzalez, Srdan Verstovsek, Zeev Estrov

Get full text

GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes by Taghi Manshouri, Ivo Veletic, Ping Li, C. Cameron Yin, Sean M. Post, Srdan Verstovsek, Zeev Estrov

Get full text

Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies by Abdallah Abou Zahr, Mohamed E. Salama, Nicole Carreau, Douglas Tremblay, Srdan Verstovsek, Ruben Mesa, Ronald Hoffman, John Mascarenhas

Get full text

Therapy-related myelofibrosis does not appear to exist by Lucia Masarova, Gabriele Todisco, Taghi Manshouri, Kate J. Newberry, Jorge E. Cortes, Hagop M. Kantarjian, Zeev Estrov, Srdan Verstovsek

Get full text

Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy by Alfonso Quintás-Cardama, Hagop Kantarjian, Susan O’Brien, Elias Jabbour, Gautam Borthakur, Farhad Ravandi, Srdan Verstovsek, Jianqin Shan, Jorge Cortes

Get full text

P1016: RUSFERTIDE (PTG-300) IMPROVES POLYCYTHEMIA VERA (PV) RELATED SYMPTOMS IN PV PATIENTS by Andrew Kuykendall, Marina Kremyanskaya, Yelena Ginzburg, Naveen Pemmaraju, Abdulraheem Yacoub, Frank Valone, Sarita Khanna, Suneel Gupta, Srdan Verstovsek, Ronald Hoffman

Get full text

PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN) by Lucia Masarova, Srdan Verstovsek, Tom Liu, Sumati Rao, Guatam Sajeev, Ryan Simpson, Weilong LI, Joseph Yang, Boris Gorsh, James Signorovitch

Get full text

A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis by Jason Gotlib, John H. Baird, Tracy I. George, Cheryl Langford, Isabel Reyes, Justin Abuel, Cecelia Perkins, Kurt Schroeder, Prithviraj Bose, Srdan Verstovsek

Get full text

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy by Naveen Pemmaraju, Hagop Kantarjian, Jianqin Shan, Elias Jabbour, Alfonso Quintas-Cardama, Srdan Verstovsek, Farhad Ravandi, William Wierda, Susan O’Brien, Jorge Cortes

Get full text

P1057: INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS by Lucia Masarova, Srdan Verstovsek, Francesca Palandri, Ruben Mesa, Claire Harrison, Balazs Dobi, Boris Gorsh, Zhaohui Wang, Catherine Ellis, Dwaipayan Patnaik, Venediktos Kapetanakis

Get full text

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies by Vikas Gupta, Claire Harrison, Elizabeth O. Hexner, Haifa Kathrin Al-Ali, Lynda Foltz, Michael Montgomery, William Sun, Prashanth Gopalakrishna, Hagop Kantarjian, Srdan Verstovsek

Get full text

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis by Uri Rozovski, Srdan Verstovsek, Taghi Manshouri, Vilma Dembitz, Ksenija Bozinovic, Kate Newberry, Ying Zhang, Joseph E. Bove, Sherry Pierce, Hagop Kantarjian, Zeev Estrov

Get full text

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States by Iman Abou Dalle, Hagop Kantarjian, Jan Burger, Zeev Estrov, Maro Ohanian, Srdan Verstovsek, Farhad Ravandi, Gautam Borthakur, Guillermo Garcia‐Manero, Elias Jabbour, Jorge Cortes

Get full text

P1024: MYLOX-1: A PHASE II STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL LOXL2 INHIBITOR GB2064 (WITH FOCUS ON BONE MARROW COLLAGEN) IN P... by Claire Harrison, John Mascarenhas, Daniela Cilloni, Richard Schlenk, Brian Jacoby, Robert J Slack, Vassilios Aslanis, Bhupinder Singh, Bertil Lindmark, Srdan Verstovsek, Raajit K Rampal

Get full text